Voice Biomarkers for Neurodegeneration
Aural Analytics is developing a voice analytics platform that aims to turn everyday speech patterns into a biomarker for brain health. This technology will give doctors and caregivers longitudinal measurements of a patient’s cognition or other neurological status without the need for clinical visits or invasive tests.
App-Based Cognitive Behavioral Therapy for Insomnia/Anxiety
Big Health is developing a suite of apps that deliver cognitive behavioral therapy for certain mental health conditions without the need for patients to make clinical visits. The company has developed Sleepio for insomnia and Daylight for generalized anxiety disorder; both apps have been proven to work in controlled trials and have generated more data in sleep-focused clinical trials than drugs like Valium or Ambien. The company has also pioneered a novel revenue model for these services.
Digital Diagnostics and Therapeutics for Autism
For autistic children, the earlier a diagnosis is made, the more effective the intervention. However, demand for pediatric neurologists is so high that many children wait more than a year to be evaluated.
Cognoa is developing a digital test that leverages machine learning and AI to analyze video of a child in question and return a diagnosis to the parent. They are also developing a digital therapeutic for children on the autistic spectrum.
Providing High-Quality, Low-Cost Healthcare with ML/AI
Curai is developing a primary care delivery platform that uses ML/AI to triage episodes of care and deliver lower-cost intervention to patients in need. It is not an expert system with pre-determined decision tree rules, but a truly self-learning platform.
With this platform, Curai aims to reduce the cost of a primary care encounter from $75 USD today to $1 or below.
They have launched a pilot program in California that is seeing 100 patients per day and plans to scale the program up nationwide.
Ieso Digital Health
Building the first AI Therapists
Ieso is the UK’s leading digital therapy provider in the space of mental health and has developed the first and only outcomes-linked mental health treatment dataset in existence. By leveraging this dataset across multiple indications (anxiety, stress, depression, PTSD), the company aims to develop next-generation mental health tools driven entirely by artificial intelligence. The company has completed early feasibility work around these AI tools and is now preparing to enter clinical development in several indications.
Quantative Assessment of Eye Movement Biomarkers
Innodem Neurosciences has developed an eye tracking platform focused on the collection of digital biomarkers for the diagnosis of a range of neurodegenerative disorders. This platform provides a streamlined, cost-effective option to perform remote testing of patients in all stages of neurodegenerative disease, increasing health equity and improving the quality of life of patients worldwide. Innodem has already been adopted as a surrogate endpoint in an ongoing MS trial, and several other partnerships are in process of being rolled out.
Multi-Modal Cognitive Tracking for Neurodegeneration
The Linus platform allows the coordinated collection of large amounts of information about digital measurements—such as voice, speech, gait, cognition and eye movement—that may have a bearing on brain health and can lead to the generation of digital biomarkers.
Applying machine learning methods of data analysis to this rich dataset provides a composite picture of each patient that enables personalized prescriptions of interventions to promote brain health.
MedRhythms is a digital therapeutics company that uses sensors, music, and software to build evidence-based, neurologic interventions to affect a variety of conditions. The company leverages the ability of music to directly stimulate the brain, resulting in neurological entrainment across the organ. MedRhythms has received a Breakthrough Device Designation for its lead program in chronic stroke recovery, and has almost completed enrollment in a pivotal clinical trial. Follow-on indications include multiple sclerosis, Parkinson’s Disease, acute stroke, and Alzheimer’s Disease.
Improving Access and Lowering Cost of Prescription Medicines
Prescryptive Health aims to eliminate the PBM middleman in the prescription drug system, saving both the system and patients money by cutting out drug rebates and reducing waste stemming from prescriptions that go unfilled due to cost. The platform provides consumers with information and tools so they have visibility into their medication pricing and options—and can engage their doctor at the point of care—when it matters most.
Reinventing Tools for Chronic Care Management
Suvera is a digital health platform that connect GPs to their patients with long-term conditions. By consistently monitoring patients’ vitals, medications, and symptoms over time, it empowers GPs to provide high-quality care to patients when they need it, and not just according to a schedule.
Suvera is developing machine learning algorithms that monitor patient trends, enabling earlier interventions in the patient’s disease course.